AlphAIAlphAI — Financial news for AI agents
investing.comOCT 162 min read$CTY

City Therapeutics prices IPO at $18 per share, raising $200M

City Therapeutics, a biotech company, priced its IPO at $18 per share, raising $200M. It will trade on Nasdaq under 'CTY'. The company focuses on RNA interference therapeutics. The offering is managed by Goldman Sachs, Jefferies, Stifel, and Oppenheimer. The SEC approved the registration on October 15, 2026.

Original reporting
investing.com
Published Oct 16, 2026, 2:49 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 16, 2026, 2:56 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefIPO
Primary signal
$CTY
Bullish
high confidence
Mentioned
$CTY
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$CTYBullishHigh
01

Why it matters

The $200 million raise provides runway for development programs and may attract speculative interest.

02

Market read

First‑time disclosure of a sizable biotech IPO, creating immediate trading opportunity.

03

What to watch

Potential underwriter overallotment risk and the company's early‑stage pipeline may limit long‑term upside.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

City Therapeutics is a clinical‑stage biotech focused on RNA interference therapeutics, seeking to fund its pipeline.

Company-level read

Ticker impact

$CTYBullishHigh confidence
Context

City Therapeutics announced pricing its IPO at $18 per share, raising $200 million, a fresh primary disclosure.

Expected impact

upward pressure as the market prices in the fresh capital raise

Evidence & confidence

The IPO pricing and sizable proceeds are disclosed for the first time, giving traders a clear entry point.

Market effects

Sector

Adds a new listed biotech to the RNA‑interference space, modestly expanding sector supply.

Regional

Boosts Nasdaq biotech listings activity on the day of the pricing.

Global

Limited to investors tracking US biotech IPOs; no broader macro effect.

Counterpoint

What could challenge this read

If demand for biotech IPOs wanes, the new shares could face weak pricing and immediate sell‑off.

Key entities

  • company
    City Therapeutics, Inc.

    Biotech firm pricing its IPO.

  • underwriter
    Goldman Sachs & Co. LLC

    Joint book‑running manager for the IPO.

Read at source← All news

StoryCity Therapeutics upsizes IPO, pricing 11.1 M shares at $18 each

Also covered by

4 outlets

Related articles

OCT 16
$CTYHighAI 8/10

City Therapeutics Prices Upsized $200 Mln IPO At $18/shr

City Therapeutics (CTY) priced its upsized IPO at $18 per share, raising $200M from 11M shares. Underwriters have a 30-day option for additional shares. Trading starts Oct 16, 2026, on Nasdaq. The company focuses on RNAi therapeutics for diseases like thromboembolic conditions and retinal diseases.

rttnews.com2 min
OCT 16
$CTYHighAI 9/10

City Therapeutics, Inc. Prices Upsized $200M IPO at $18

City Therapeutics priced an upsized IPO of 11.1M shares at $18 each, raising $200M. Shares will begin trading on Nasdaq as CTY on Oct. 16, 2026, subject to conditions. The company has no prior public trading history and plans to use proceeds for its clinical-stage RNAi pipeline.

tradingview.com1 min
OCT 9
$CTYHighAI 8/10

City Therapeutics IPO: RNAi biotech seeks up to $185 million

City Therapeutics, a biotech developing RNAi drugs, filed for an IPO seeking up to $184.7M, offering 9.7M shares at $17-$19 each. The company plans to list on Nasdaq under CTY. Its lead candidate, CITY-FXI, showed promising Phase 1 trial results. The company has raised $238.8M in equity and reported a $53.4M net loss for H1 2026. Proceeds will fund clinical development and research. (350 characters)

finance.yahoo.com2 min
OCT 16
$IAMHighAI 9/10

Iambic Therapeutics IPO Raises $150M, Stock Jumps

Iambic Therapeutics (IAM) raised $150M in its IPO, priced at $16, and saw shares jump 18% to close at $18.91. The company, which uses AI for drug discovery, has partnerships with AbbVie, Takeda, and Nvidia. It reported $12.8M revenue and a $50.1M net loss for H1 2026. Proceeds will fund oncology programs.

briefs.co2 min